Gilead Sciences has agreed to acquire Tubulis in a deal worth up to $5 billion, aiming to strengthen its cancer treatment pipeline. The acquisition highlights growing investment in advanced therapies.

Tubulis specialises in antibody-drug conjugates, a targeted cancer treatment designed to deliver drugs directly to tumour cells. This approach reduces damage to healthy tissue.

Gilead has been expanding its oncology portfolio as part of its long-term growth strategy. The deal reflects increasing competition in the biotech sector.

The acquisition is expected to enhance research capabilities and accelerate the development of new treatments. Investors are watching closely for integration progress.

Analysts say the move underscores continued innovation in healthcare. Pharmaceutical companies are relying on acquisitions to drive growth and remain competitive.

Source: Reuters